What is Dubin Johnson Syndrome? (Definition)
(Symptoms, Causes & Treatment)
According to the U.S. National Library of Medicine, Dubin-Johnson syndrome is a very rare inherited condition or disorder which is identified by jaundice (a yellowing of the skin and whites of the eyes caused by the inability of the body to remove bilirubin from the liver). In most affected people jaundice appears during adolescence or early adulthood, although a few individuals have been diagnosed soon after birth. Jaundice is typically the only symptom of Dubin-Johnson syndrome, but some people also experience weakness, mild upper abdominal pain, nausea, and/or vomiting.
Complications are unusual, but may include the following:
- Reduced liver function
- Severe jaundice
See below for updated news and information regarding Dubin Johnson Syndrome including new medical research, treatment options and advancements.
Latest Dubin Johnson Syndrome Research – Treatment News, Discoveries and Findings
No recent news regarding Dubin Johnson Syndrome is available.
Clinical Resources: Treatment Therapies & Guidelines
Clinical Trials – Investigational Therapies
For information on current clinical trials, visit www.clinicaltrials.gov. This is a searchable registry and results database of federally and privately supported clinical trials taking place in the U.S and abroad. ClinicalTrials.gov provides information about a trial’s purpose, who may participate, locations, and phone numbers. This information should be used in conjunction with advice from health care professionals.
For information about clinical trials being conducted at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Toll Free: (800) 411-1222
TTY: (866) 411-1010
For information about clinical trials conducted in Europe, visit: https://www.clinicaltrialsregister.eu/ctr-search/search
If you have experience dealing with this disease or condition (especially with regard to symptoms, diagnosis, causes or treatment), please share below: